Context Therapeutics Submitted An FDA Investigational New Drug To Begin Phase 1 Dose Escalation And Expansion Trial Of CTIM-76 For Claudin 6-Positive Gynecologic And Testicular Cancers
Context Therapeutics 提交了一种美国食品药品管理局的研究性新药,将开始针对克劳丁 6 阳性妇科和睾丸癌的 CTIM-76 的 1 期剂量递增和扩展试验